Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV:
LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech
company that leverages advancements in science and technology to
build breakthrough ventures that transform human wellness, reports
that European clinical research demonstrated that the active
ingredient in
Serenity, the newest product from
its U.S. biosciences subsidiary Mikra Cellular Sciences Inc.
(“Mikra”), is equally effective as a prescription-only
benzodiazepine in treating the symptoms of anxiety.
In a multi-center, double-blind, randomized
controlled trial1, European researchers determined that the active
ingredient in Serenity, steam extract of lavender
oil, was as effective as lorazepam (trade name: AtivanTM) in
treating generalized anxiety disorder (GAD):
In conclusion, our
results demonstrate that [lavender oil] is as effective as
lorazepam in adults with GAD... Since lavender oil showed no
sedative effects in our study and has no potential for drug abuse,
it appears to be an effective and well tolerated alternative to
benzodiazepines for amelioration of generalised anxiety.
This research was particularly noteworthy
because benzodiazepines, while widely prescribed for anxiety, carry
substantial risk of dependency and of seizures in case of
withdrawal2.
Furthermore, concerning new research related to
anxiety, presented in November 2023 at a scientific session of the
American Heart Association3 revealed that:
Even after adjusting
for risk factors such as high blood pressure, high cholesterol,
smoking and Type 2 diabetes, as well as income and education,
researchers found that higher cumulative stress was: associated
with a 22% increased risk of atherosclerosis, in which plaque
builds up in the arteries reducing adequate blood flow; and
associated with a 20% increased risk of overall cardiovascular
disease, including coronary artery disease and heart failure.
“We are not surprised by the growing body of
research revealing the detrimental effects of anxiety on physical
as well as mental and emotional health,” said Meni Morim, CEO of
Lifeist. “It was this understanding that drove us to accelerate the
launch of Serenity. We appreciate the ongoing
research shedding light on this affliction that affects far too
many people, and on the benefits that the natural ingredient in
Serenity brings to the table in addressing
it.”
The active ingredient in
Serenity is a steam extract of lavender oil which
has been extensively clinically studied as a frontline solution to
anxiety. What sets Serenity apart from competing
products is the consistent GCMS-verified dose4 of the active
ingredient combined with the integration of Mikra's proprietary
polyterpene blend that provides an agreeable flavor and aftertaste,
addressing a common complaint voiced by early adopters of competing
lavender oil products of a "perfume-like" taste. With Lifeist's
expertise with fragrant and flavorful botanicals,
Serenity is poised to become the best tasting
lavender oil extract supplement on the market. Plus,
Serenity ships with a full 30-day supply in every
bottle, as compared to the typical 7- or 14-day supply sold in
competing lavender-based products.
To order Serenity, customers
should visit www.wearemikra.com/products/serenity and are
encouraged to sign up for updates and promotional offers at
https://bit.ly/serenity-sign-up.
Mikra is pushing biosciences beyond the expected
with the belief that it is possible to add more active, vigorous,
enjoyable, and valuable years to your life through protecting and
maintaining your cellular health.
Lifeist is committed to bringing natural
products -- backed by real science -- to current and future
customers and looks forward to introducing new products in the
first half of 2024.
About Lifeist Wellness
Inc. Sitting at the forefront of the
post-pandemic wellness revolution, Lifeist leverages advancements
in science and technology to build breakthrough companies that
transform human wellness. Portfolio business units include:
CannMart, which operates a B2B wholesale distribution business
facilitating recreational cannabis sales to Canadian provincial
government control boards including for CannMart Labs, a BHO
extraction facility producing high margin cannabis 2.0 products;
Australian Vapes, one of Australia’s largest online retailers of
vaporizers and accessories; and Mikra, a biosciences and consumer
wellness company developing and selling innovative therapies for
cellular health. Information on Lifeist and its businesses can
be accessed through the links
below: www.lifeist.com https://cannmart.com https://wearemikra.com www.australianvaporizers.com.au
Contact: Meni
Morim CEO Lifeist Wellness Inc. Ph:
647-362-0390 Email: ir@lifeist.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release or has in any way approved
or disapproved of the contents of this press
release.
Forward Looking
Information This news release contains
“forward-looking information” within the meaning of applicable
securities laws. All statements contained herein that are not
historical in nature contain forward-looking information.
Forward-looking information can be identified by words or phrases
such as “may”, “expect”, “likely”, “should”, “would”, “plan”,
“anticipate”, “intend”, “potential”, “proposed”, “estimate”,
“believe” or the negative of these terms, or other similar words,
expressions and grammatical variations thereof, or statements that
certain events or conditions “may” or “will”
happen.
The forward-looking information contained
herein, including, without limitation, statements related to the
introduction of new products in the first half of 2024 and the
anticipated benefits of using Serenity instead of
antidepressants to treat anxiety are made as of the date of this
news release and are based on assumptions management believed to be
reasonable at the time such statements were made, including without
limitation, that Mikra will be able to develop new products as
anticipated and in a timely manner, expectations
relating to the effectiveness of lavender oil and its extracts in
treating anxiety as demonstrated in published materials and
studies, its expectation that the nutraceutical market will develop
as currently anticipated, the nutraceutical market will continue to
be a multi-billion dollar high-margin market, expectations that
Serenity will gain market acceptance as a natural
supplement alternative for the treatment of anxiety, along with the
expansion of the market for nutraceutical products, as well as
other considerations that are believed to be appropriate in the
circumstances. While we consider these assumptions to be reasonable
based on information currently available to management, there is no
assurance that such expectations will prove to be correct. By its
nature, forward-looking information is subject to inherent risks
and uncertainties that may be general or specific and which give
rise to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct, and that objectives, strategic
goals and priorities will not be achieved. A variety of factors,
including known and unknown risks, many of which are beyond our
control, could cause actual results to differ materially from the
forward-looking information in this news release. Such factors
include, without limitation: the failure to develop new products as
anticipated and in a timely manner, the failure of
Serenity, a natural supplement alternative, to
demonstrate a notable effectiveness in treating general anxiety
disorder or other anticipated health benefits, the inability of the
Company to develop Mikra’s business as anticipated, unanticipated
changes to current regulations that would adversely impact Mikra’s
business, unforeseen developments that would delay Mikra’s ability
to sell Serenity, the risk that the expected
demand for nutraceutical products in general and those of Mikra in
particular does not develop as anticipated and risks relating to
the Company’s ability to execute its business strategy and the
benefits realizable therefrom. Additional risk factors can also be
found in the Company’s current MD&A filed under the Company’s
SEDAR profile at www.sedarplus.ca. Readers are cautioned not
to put undue reliance on forward-looking information. The Company
undertakes no obligation to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise, except as required by applicable law. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement.
Source: Lifeist Wellness Inc.
_______________________
1 A multi-center, double-blind, randomized study of lavender oil
in comparison to Lorazepam for generalized anxiety disorder -
https://pubmed.ncbi.nlm.nih.gov/19962288/.
TM All trademarks are the property of their
respective owners.
2 Benzodiazepine withdrawal seizures and management
- https://pubmed.ncbi.nlm.nih.gov/21815323/
3 Depression, anxiety and stress linked to poor heart health in
two new studies -
https://newsroom.heart.org/news/depression-anxiety-and-stress-linked-to-poor-heart-health-in-two-new-studies.
4 GCMS-verified doses have been rigorously
confirmed through Gas Chromatography-Mass Spectrometry analysis,
and provide a high level of confidence in the accuracy and
reliability of the specified dosage, making it a crucial aspect of
quality control in industries where precise and consistent dosing
is essential for safety and efficacy.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9704211f-261a-450a-8196-9fffac147d7b
Lifeist Wellness (TSXV:LFST)
Historical Stock Chart
From Apr 2024 to May 2024
Lifeist Wellness (TSXV:LFST)
Historical Stock Chart
From May 2023 to May 2024